UNC Metastatic Cancer Radiation Therapy Registry

NCT06306924 | Recruiting DMC

• 1 other identifier: LCCC2303
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this registry is to collect clinical data from participants attending UNC Hospitals who present with metastatic cancer and are evaluated to receive radiation therapy as part of their standard of care treatment. The goal of this study is to provide a foundation for studies designed to identify projects across the translational continuum related to metastatic cancer and radiation therapy treatment. The relevant clinical data will be linked to patient-reported outcomes (PROs) thus allowing for a unique and robust dataset. Ultimately, this registry will provide current and future studies with the ability to analyze the correlation of radiation therapy regimens with metastatic cancer outcomes.

Conditions

Cancer; Metastatic Cancer

Keywords

radiation therapy

Outcome Measures

Primary Outcomes (1)

• Clinical Data

  Clinical data and radiological assessments from participants with metastatic cancer receiving radiation therapy as a part of the standard of care will be collected.

  Up to 1 month

Secondary Outcomes (1)

• Patient reported outcomes (PRO)

  Baseline, 1 month, 3 months, 6 months, 9 months, and 12 months

Study Arms (1)

Palliative radiation therapy

Subjects who are with metastatic cancer receive palliative radiation therapy.

Radiation: Radiation therapy

Interventions

Radiation therapy RADIATION

Subjects with metastatic cancer receive radiation therapy.

Palliative radiation therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects with metastatic cancer receiving palliative radiation therapy at the University of North Carolina Chapel Hill.

You may qualify if:

• Written informed consent was obtained to participate in the study and HIPAA
• Authorization for release of personal health information. Ability to understand and willingness to sign informed consent
• Diagnosed with or is suspected to have metastatic cancer.
• Age ≥ 18 years at the time of consent.
• Evaluated to receive radiation therapy as part of their standard-of-care treatment plan.

You may not qualify if:

• Any serious medical or psychiatric disorder that would interfere with the participant's ability to give informed consent.

Sponsors & Collaborators

• UNC Lineberger Comprehensive Cancer Center: lead

Study Sites (1)

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, 27599, United States

RECRUITING

Related Links

• University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials

MeSH Terms

Conditions

Neoplasms; Neoplasm Metastasis

Interventions

Radiotherapy

Condition Hierarchy (Ancestors)

Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

• Shivani Sud, MD

  UNC Lineberger Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kadiata Toumbou

CONTACT

(202) 569-3721; kadiata@email.unc.edu

Victoria Xu

CONTACT

victoria_xu@med.unc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 5, 2024
• First Posted: March 12, 2024
• Study Start: April 21, 2024
• Primary Completion (Estimated): May 1, 2033
• Study Completion (Estimated): May 1, 2033
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)